mRNA therapeutics in cancer immunotherapy

Abstract

Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large scale Good Manufacturing Practice-grade mRNA production, mRNA is ideally poised not only for off-the shelf cancer vaccines but also for personalized neoantigen vaccination. The ability to stimulate pattern recognition receptors and thus an anti-viral type of innate immune response equips mRNA-based vaccines with inherent adjuvanticity. Nucleoside modification and elimination of double-stranded RNA can reduce the immunomodulatory activity of mRNA and increase and prolong protein production. In combination with nanoparticle-based formulations that increase transfection efficiency and facilitate lymphatic system targeting, nucleoside-modified mRNA enables efficient delivery of cytokines, costimulatory receptors, or therapeutic antibodies. Steady but transient production of the encoded bioactive molecule from the mRNA template can improve the pharmacokinetic, pharmacodynamic and safety properties as compared to the respective recombinant proteins. This may be harnessed for applications that benefit from a higher level of expression control, such as chimeric antigen receptor (CAR)-modified adoptive T-cell therapies. This review highlights the advancements in the field of mRNA-based cancer therapeutics, providing insights into key preclinical developments and the evolving clinical landscape.

Cited by papers we hold 13

• Trials and Tribulations of MicroRNA Therapeutics · 2024
  No notice
• Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy · 2024
  No notice
• mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications · 2023
  No notice
• Research Advances on the Stability of mRNA Vaccines · 2023
  No notice
• Emerging non-viral vectors for gene delivery · 2023
  No notice
• Neoantigens: promising targets for cancer therapy · 2023
  No notice
• mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy · 2022
  Not checked
• Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies · 2022
  No notice
• Cancer vaccines as promising immuno-therapeutics: platforms and current progress · 2022
  No notice
• mRNA vaccines for cancer immunotherapy · 2022
  No notice
• CAR-T cell combination therapy: the next revolution in cancer treatment · 2022
  No notice
• RNA-based therapeutics: an overview and prospectus · 2022
  No notice
• Trial watch: intratumoral immunotherapy · 2021
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.